Newsletters

Journalism of Courage

Cipla Limited: A Global Pharmaceutical Giant Cipla Limited, headquartered in Mumbai, stands as a prominent multinational pharmaceutical company with a global reach. Its core focus lies in developing and manufacturing medications targeting a wide spectrum of diseases, including respiratory ailments, cardiovascular conditions, arthritis, diabetes, depression, and paediatric illnesses. The company's extensive manufacturing network encompasses 47 locations worldwide, facilitating the distribution of its products to 86 countries. This extensive global presence underscores Cipla's significant role in the international pharmaceutical market. Holding the position of the third-largest drug producer in India, Cipla's contribution to the nation's healthcare landscape is undeniable. The company's commitment to developing treatments for a diverse range of medical conditions reinforces its dedication to improving global health outcomes. Cipla's substantial manufacturing capacity and widespread distribution network solidify its status as a major player in the pharmaceutical industry.

Image Source : Wikipedia

Company type Public
Industry Pharmaceuticals
Founded 1935 (90 years ago) (1935)
Founders Khwaja Abdul Hamied
Headquarters Mumbai, Maharashtra, India
Area served Worldwide
Revenue ₹25,455 crore (US$2.9 billion) (FY24)
Net income ₹4,106 crore (US$470 million) (FY24)
Number of employees 22,036
Subsidiaries Invagen Pharmaceuticals
Website www.cipla.com

Related Other Pages:

Biocon and

Sun Pharmaceuticals

Cipla history

Last Updated : 25/03/25, 11:12 PM

Cipla: A Legacy of Pharmaceutical Innovation Established in Mumbai in 1935 as Chemical, Industrial & Pharmaceutical Laboratories, Cipla, under the stewardship of Khwaja Abdul Hamied, laid the foundation for its enduring legacy. Following Hamied's death in 1972, his son Yusuf Hamied, a Cambridge-educated chemist, assumed leadership. A pivotal moment arrived in 1995 with the launch of Deferiprone, the world's first oral iron chelator. Cipla's commitment to affordable healthcare gained global recognition during the early 2000s AIDS epidemic. Through reverse engineering, Cipla created a significantly cheaper version of a vital antiretroviral medication, making it accessible to African nations. This initiative is estimated to have impacted a substantial portion of AIDS patients in developing countries. Further demonstrating its commitment to affordable healthcare, Cipla successfully reverse-engineered Tamiflu during the 2006 avian flu pandemic, offering it at substantially lower prices. Strategic acquisitions, including Cipla-Medpro in South Africa (2013), InvaGen and Exelan Pharmaceuticals in the US (2015), and Actor Pharma in South Africa (2023), have broadened Cipla's global reach and product portfolio. The company's recent foray into digital therapeutics (2019) and the acquisition of Ivia Beaute's cosmetics business (2024) signify its diversification strategy. Cipla’s consistent innovation and commitment to accessibility continue to shape its global standing in the pharmaceutical industry.